fabrazyme造句

• Fabrazyme on its own is not big enough to turn around Genzyme, Tanner said.
• TKT's Replagal and Genzyme's Fabrazyme are two versions of the same protein.
• Its only hope is to convince regulators that Replagal is safer or more effective than Fabrazyme.
• Replagal and Fabrazyme, both approved in Europe, replace an enzyme missing in Fabry patients.
• A detailed report on Genzyme's drug Fabrazyme is also expected to be published in a respected medical journal.
• It isn't necessarily a sign that the agency won't approve Genzyme's drug, called Fabrazyme.
• We feel very good about this moment and very good for patients in the US who finally have access to Fabrazyme.
• Both Replagal and Genzyme's drug, Fabrazyme, consist of an enzyme that is lacked by patients with Fabry disease.
• Genzyme makes a kidney drug, Renagel, and Fabrazyme, a treatment for Fabry's disease regulators approved last month.
• The pharmaceutical company Genzyme produces synthetic agalsidase beta ( INN ) under the trade name Fabrazyme for treatment of Fabry's disease.
• Analysts estimate that Fabrazyme and Aldurazyme could eventually bring in as much as $ 300 million to $ 500 million each in annual sales.
• Genzyme Corp .'s drug, known as Fabrazyme, was approved by the FDA in April and given seven years market exclusivity.
• The agency could approve Replagal and later approve Fabrazyme, allowing them to share the orphan drug status and duke it out in the marketplace.
• It is developing four more drugs, including Fabrazyme, a enzyme replacement drug for Fabry disease, which affects more than 2, 000 males.
• Replagal would be TKT's first marketed product in the United States whereas Fabrazyme would represent a relatively modest percentage of Genzyme's US sales.
• Still, if such accelerated approval were granted, Genzyme would have to do more studies to confirm that Fabrazyme actually does decrease pain or organ damage.
• Sales of the Fabry's Disease treatment Fabrazyme more than tripled to $ 38.1 million from $ 11.8 million a year earlier.
• Revenue, came to $ 491.3 million in the first quarter, driven by sales of the company's Cerezyme, Renagel and Fabrazyme treatments.
• The multicenter study, due to start next year, calls for Genzyme to examine several issues, including Fabrazyme's ability to prevent deterioration of kidney function.
• But, he said, Fabrazyme cleared more of the fatty lipids that accumulate in Fabry patients, causing pain and organ damage, than TKT's drug.